One named operator on your dials. No per-meeting commissions. No rotating bench. This is the honest read on where CIENCE wins, where the model costs you, and where 2CT wins. Twelve buying criteria, four framework-backed reasons, three scenarios.
Both vendors claim to book meetings for B2B teams. The model underneath is where the bill, the turnover, and the lead quality actually come from. Twelve rows. Read the ones that matter to your buying cycle.
CIENCE built a platform business. 2CT built a sales floor. Both are valid. They behave very differently inside your pipeline.
Your operator sits on a managed floor next to a QA lead and a sales manager. They run one ICP, one playbook, one stack. They dial every working day. Their name is on your MSA. When they get sick we tell you. When they leave we ramp the next one on our cost.
CIENCE earns when held meetings hit the calendar. The graph8 platform earns its monthly fee regardless. SDRs are assigned from a pool, which means the human running your campaign in month 3 may not be the human you onboarded.
The value equation is the fastest way to compare outbound vendors honestly. Increase the dream outcome and the perceived likelihood of achievement. Decrease the time delay and the effort. The numbers underneath the invoice tell you which vendor moves the equation in your favour.
No vendor is right for everyone. Three honest cases where CIENCE is the better pick than 2CT.
If you do not run Apollo, Clay, or HubSpot and you want one vendor to provide list, sequencer, intent signals, and the SDR layer all in one bill, CIENCE bundles that. 2CT does not. We expect you to bring or buy your stack and we run inside it.
If your CFO will only sign a deal where you pay strictly per held meeting, with no monthly base, CIENCE has a SKU for that. 2CT does not run pay-per-meeting. We pay our operators a real monthly wage with bonuses. The incentive structure is the product.
If procurement needs a vendor on the Inc 5000 with a logo wall featuring Okta and Shutterstock, CIENCE checks that box. 2CT is a younger floor. Our wall is being built one named buyer at a time.
Three structural reasons, each backed by a framework not by a marketing slogan.
Cold email reply rates in 2026 sit between 0.5 and 2 percent for most B2B ICPs, with deliverability tightening every quarter. A trained operator on the dials runs 40 to 70 connects per day with a 5 to 12 percent conversation-to-meeting ratio. 2CT is not anti-email. We are anti email-as-the-headline-channel. Phone is the highest-yield activity per minute and the activity buyers most reliably avoid.
Pipeline takes 60 to 90 days to compound. If you have to re-onboard a rep in month three, you are not three months in, you are zero months in. We absorb that risk by naming the operator on the contract and re-ramping at our cost if they leave. In value terms that is a direct improvement to perceived likelihood: the same operator, same script, same call list, every working day, the longer they run the better the conversion gets.
A meeting that does not progress to a next-step inside 14 days does not count as pipeline at 2CT. That standard kills weak meetings before they reach your AE. CIENCE's per-held-meeting model rewards the opposite behaviour. Read the CIENCE contract closely on what "held" means and how it is verified. The principle is simple: a real meeting requires buyer awareness of a problem. Anything less is calendar noise.
Both can do this. 2CT wins on cost per equivalent seat, single-rep minimum, and 30 days notice. CIENCE wins on brand-name comfort if your board needs to see a known logo on the slide.
CIENCE books and hands back. 2CT runs the Outbound Desk plus the Closing Desk that takes discovery and demo. Handoff stays internal, inside one team. Your funnel does not break at the seam.
CIENCE's effective break-even sits several months in once setup and platform fees are added. 2CT launches in 10 business days and runs month to month with 30 days notice after the first 90 days. Then month to month.
Fully managed plan carries the 5x pipeline guarantee.